| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/18/2006 | CN1723036A Methods of increasing platelet and hematopoietic stem cell production |
| 01/18/2006 | CN1723035A Use of ghrelin for treating malnutrition in gastrectomised individuals |
| 01/18/2006 | CN1723034A Composition and method for treating diabetes |
| 01/18/2006 | CN1723033A Composition for reducing caloric intake |
| 01/18/2006 | CN1723032A Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 01/18/2006 | CN1723014A Agent for dissolving dental calculi and dental caries |
| 01/18/2006 | CN1721535A Human secreted protein hZG16 |
| 01/18/2006 | CN1721534A Human secreted protein hPAP21 |
| 01/18/2006 | CN1721533A Fusion protein of IL2 and single chain antibody against GD2, its encoding genes and use thereof |
| 01/18/2006 | CN1721528A Novel human complement C1r-like serine proteinase analogue, and its encoding sequence and use |
| 01/18/2006 | CN1721525A Method for inducing neural differentiation and composition |
| 01/18/2006 | CN1721447A Modified peptides as therapeutic agents |
| 01/18/2006 | CN1721444A Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 01/18/2006 | CN1721443A Human receptor proteins, related reagents and methods |
| 01/18/2006 | CN1721442A Proteins producing an altered immunogenic response and methods of making and using the same |
| 01/18/2006 | CN1721441A Novel hepatic factor of human embryo |
| 01/18/2006 | CN1721438A Human secreted protein hCGI-143 |
| 01/18/2006 | CN1721432A Peptide specifically associated with front surface antigen zone of large protein of human hepatitis B virus surface antigen and uses thereof |
| 01/18/2006 | CN1721431A Novel alpha-melanocyte stimulating hormone analogue and use thereof |
| 01/18/2006 | CN1721004A Biological active antibiotic dressing |
| 01/18/2006 | CN1720995A The treatment of respiratory diseases |
| 01/18/2006 | CN1720994A Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 01/18/2006 | CN1720989A Sustained release microsphere of epidermal growth factor, its preparation method and application |
| 01/18/2006 | CN1720904A Hemodilution facilitated by monitoring oxygenation status |
| 01/18/2006 | CN1720902A Method for preparing biological degradable polymer drug-carried fine particle by supercritical anti-solvent process |
| 01/18/2006 | CN1720876A Uterus neck skin tissue engineering scaffold and method for producing the same |
| 01/18/2006 | CN1237185C SARS coronavirus 3Cl protease two-dimensional model and medicine preventing SARS |
| 01/18/2006 | CN1237184C Target for medicine against SARS-Cov and medicine screening method and medicine against SARS |
| 01/18/2006 | CN1237076C Polypeptide variants with altered effector function |
| 01/18/2006 | CN1237075C Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 01/18/2006 | CN1236831C Compositions for protein delivery via the pulmonary route |
| 01/18/2006 | CN1236817C Novel mixtures of microbial enzymes |
| 01/18/2006 | CN1236816C Tissue volume reduction |
| 01/18/2006 | CN1236815C Application of integrin antagonists in preparation of medicine for treating multiple myeloma and myeloma-induced bone resorption |
| 01/18/2006 | CN1236814C Faluopeinan medicine composition containing glutathione |
| 01/18/2006 | CN1236813C Self-emulsifying compositions for drugs poorly soluble in water |
| 01/18/2006 | CN1236757C Slimming composition contg. substance inducing IL-6 production |
| 01/17/2006 | US6987178 A recombinant expression vector; an isolated nucleic acid molecule; diagnosis of high blood pressure, obesity |
| 01/17/2006 | US6987173 Process for the preparation of active somatotropin from inclusion bodies |
| 01/17/2006 | US6987172 Multifunctional single chain glycoprotein hormones comprising three or more β subunits |
| 01/17/2006 | US6987171 Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
| 01/17/2006 | US6987169 Nucleotide sequences coding polypeptide for use in the treatment of cancer, heart and viral diseases |
| 01/17/2006 | US6987168 Tryptase inhibitor proteins derived from blood-feeding anthropod ectoparasites |
| 01/17/2006 | US6987167 Process for production of the somatostatin analog, octreotide |
| 01/17/2006 | US6987129 Treating vaginismus, dyspareunia, interstitial cystitis, vulvodynia, vulvar vestibulitis, nonspecific urethritis, female sexual arousal orgasmic disorders or increasing vaginal lubrication, etc. |
| 01/17/2006 | US6987128 Compounds of the N-acylamino amide family, compositions comprising same, and uses |
| 01/17/2006 | US6987123 A substituted pyrrole-1-yl-alkyloxy-aryl-2-alkyloxypropanoate derivatives, antilipiemic agents, anticholesterol agents |
| 01/17/2006 | US6987120 Pharmaceutical compounds |
| 01/17/2006 | US6987103 Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
| 01/17/2006 | US6987102 Methods to mobilize progenitor/stem cells |
| 01/17/2006 | US6987098 Health supplement |
| 01/17/2006 | US6987096 genetic engineering of a cyanovirin; gene therapy; exogenous gene expression; use alone or in combination with antiviral agents such as AZT; AIDS therapy |
| 01/17/2006 | US6987090 Use of 3-position cyclosporin derivatives for hair growth |
| 01/17/2006 | US6987089 Mouse CIA protein and CIA gene having anti-apoptotic activity as a selective inhibitor of CAD interacting ASK1 use thereof |
| 01/17/2006 | US6987088 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 01/17/2006 | US6987021 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 01/17/2006 | US6987014 Isolated nucleic acid molecules encoding human drug metabolizing proteins |
| 01/17/2006 | US6987008 Mutant nucleoside-5'-phosphate-producing enzyme with ability for transphosphorylation activity and/or phosphatase activity; amino acid sequence with replacements elucidated; genes; recombinant DNA; microorganisms; crystals |
| 01/17/2006 | US6987006 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |
| 01/17/2006 | US6987005 Where the human SNORF33 receptor has the amino acid sequence SEQ ID NO: 6; encoded by ATCC deposited plasmids; activated by either tyramine, tryptamine, or beta -phenyl-ethylamine; vectors; cells; membranes; nervous system disorders |
| 01/17/2006 | US6987004 Discovery of four mammalian genes designated CalDAG-GEFI, CalDAG-GEFII, cAMP-GEFI, and cAMP-GEFII, which encode proteins having a substrate specificity for Rap1A; dual binding domains for calcium and diacylglycerol; anticarcinogenic agents |
| 01/17/2006 | US6987003 Modulation of RNA transport to the rough endoplasmic reticulum by staufen proteins; isolated nucleic acids encoding this protein and vectors and host cells expressing them; nucleic acid sequences and their encoded amino acid sequences; viricides |
| 01/17/2006 | US6987001 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| 01/17/2006 | US6986996 Using anti-heparanase antibody to bind heparanase encoded by amino acid sequence no.1 for monitoring heparanase protein expression of heparanase gene in white blood cells in vitro; drug delivery targets; diagnosis of tumors, cancer and metastasis |
| 01/17/2006 | US6986984 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
| 01/17/2006 | US6986903 Methods for treatment of human skin damaged by laser treatment or chemical peelings and compositions useful in such methods |
| 01/17/2006 | US6986894 Methods for the treatment of coagulation disorders with lipoprotein associated coagulation inhibitor (LACI) |
| 01/17/2006 | US6986893 Administering botulinum toxin in order to reduce mucus secretion of patient, wherein mucus secretion is not a symptom of rhinorrhea |
| 01/17/2006 | US6986890 Anti-human VEGF receptor Flt-1 monoclonal antibody |
| 01/17/2006 | US6986755 Sensor system including port body |
| 01/17/2006 | CA2346171C Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid |
| 01/17/2006 | CA2086425C Fibroblast growth factor receptors |
| 01/12/2006 | WO2006004959A2 Pegylated interferon alpha-1b |
| 01/12/2006 | WO2006004907A2 Methods of inhibiting viral replication |
| 01/12/2006 | WO2006004878A1 Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof |
| 01/12/2006 | WO2006004868A2 Bioactive peptide coatings |
| 01/12/2006 | WO2006004696A2 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 01/12/2006 | WO2006004675A2 Production of tissue factor in plants |
| 01/12/2006 | WO2006004633A2 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/12/2006 | WO2006004588A2 Immunodynamic complexes and methods for using and preparing such complexes |
| 01/12/2006 | WO2006004173A1 Viral particle-like construct and method of forming the same under physiological conditions |
| 01/12/2006 | WO2006004105A1 Method of producing peptide mixture, method of producing fermented milk containing antihypertensive peptide and method of producing antihypertensive peptide preparation |
| 01/12/2006 | WO2006003427A1 A protein involved in carcinoma |
| 01/12/2006 | WO2006003384A1 Treatment of cancer |
| 01/12/2006 | WO2006003213A1 Diaminooxidase-containing pharmaceutical compositions |
| 01/12/2006 | WO2006002968A2 Use of a bacterial phosphoenolpyruvate carboxylase |
| 01/12/2006 | WO2006002854A2 Tie receptor and tie ligand materials and methods for modulating female fertility |
| 01/12/2006 | WO2006002853A1 Synthesis of spider dragline and/or flagelliform proteins |
| 01/12/2006 | WO2006002827A1 Proteins of natural origin and materials made therefrom |
| 01/12/2006 | WO2006002646A2 Novel carbamylated epo and method for its production |
| 01/12/2006 | WO2006002453A2 Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface |
| 01/12/2006 | WO2005118613A3 Antibacterial amide macrocycles |
| 01/12/2006 | WO2005110456A3 T-cell death-inducing epitopes |
| 01/12/2006 | WO2005097088A3 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| 01/12/2006 | WO2005090573A3 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 01/12/2006 | WO2005074981A3 Inhibitors of tgf-r signaling for treatment of cns disorders |
| 01/12/2006 | WO2005070448A3 Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease |
| 01/12/2006 | WO2005049027A3 Combinations useful for the treatment of neuronal disorders |
| 01/12/2006 | WO2005045039A3 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/12/2006 | WO2004080401A3 Oral insulin therapies and protocol |